Eric W. Roberts

Founding Managing Director

In 2012, Mr. Roberts co-founded Valence Advantage Life Sciences. Prior to Valence Life Sciences, Mr. Roberts managed Caxton Advantage which he co-founded in 2004.   Mr. Roberts has 27 years of experience in the life sciences industry and has completed over 250 financings and merger transactions.  He has funded a number of breakthrough therapies including several of the leading cancer drugs such as Celgene’s top-selling cancer drug, Revlimid, Imclone’s Erbitux and Celator’s VYXEOS. Prior to Caxton Advantage, he was Managing Director and Co-Head of the Global Healthcare Investment Banking Group at Lehman Brothers. He also served as a member of the Investment Banking Management Committee and as a member of the screening committee for the Lehman Brothers Healthcare Venture Capital Fund. Mr. Roberts was also a Managing Director, Partner and founder of the Life Sciences Department at Dillon, Read & Co. Inc. which was ultimately merged into UBS. At UBS, Mr. Roberts ran the Life Sciences investment banking team. In addition, Mr. Roberts worked at Citicorp in the Citicorp Venture Capital (CVC) group before Dillon Read. Mr. Roberts received a B.S. in Economics from the Wharton School of the University of Pennsylvania.   Mr. Roberts serves as a Director of Invuity, Inc. and Vivus, Inc. and previously served as a Director of Gemin X Pharmaceuticals and Regado Biosciences.  He is a current Director of the Carey Institute for Ecosystem Studies, the Atlantic Salmon Federation and is a past Director of the American Museum of Fly Fishing.


August 21, 2013

Regado Completes $55 Million IPO